calcipotriene
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- calcipotriene
- Generic name
- CALCIPOTRIENE
- Manufacturer
- Northstar Rx LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- a882ef4f-603e-4421-97ae-2c78822c767a
- SPL ID
- 3d61ea62-e1eb-45c1-8137-eda163a24a41
- Version
- 5
- Effective date
- 2026-10-06
- Source export date
- 2026-11-13
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:54:32
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 205772 | derived:openfda.application_number |
| application number | ANDA205772 | openfda.application_number | |
| brand name | calcipotriene | openfda.brand_name | |
| generic name | CALCIPOTRIENE | openfda.generic_name | |
| manufacturer name | Northstar Rx LLC | openfda.manufacturer_name | |
| ndc | package | 16714-763-01 | openfda.package_ndc |
| ndc | package | 16714-763-02 | openfda.package_ndc |
| ndc | product | 16714-763 | openfda.product_ndc |
| ndc11 | package | 16714076302 | derived:openfda.package_ndc |
| ndc11 | package | 16714076301 | derived:openfda.package_ndc |
| rxcui | 313921 | openfda.rxcui | |
| spl id | 3d61ea62-e1eb-45c1-8137-eda163a24a41 | id | |
| spl set id | a882ef4f-603e-4421-97ae-2c78822c767a | set_id | |
| unii | 143NQ3779B | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Contact dermatitis, including allergic contact dermatitis, has been observed with the use of calcipotriene cream.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Clinical Trials Experience In controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients. Postmarketing Experience The following adverse reactions have been identified during postapproval use of calcipotriene Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Metabolism and nutrition disorders: hypercalcemia Renal and urinary disorders: hypercalciuria Skin and subcutaneous tissue disorder: application site edema, application site pain, contact dermatitis (including allergic contact dermatitis), depigmentation, dry skin, erythema, hyperpigmentation, hypopigmentation, photosensitivity, rash (including erythematous, maculo-papular, and pustular), skin burning sensation, skin exfoliation, and urticaria. To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.